Levisetti will also discuss the company’s second clinical candidate, CUE-102, currently in evaluation in a Phase 1 trial for patients with Wilms’ Tumor 1 (WT1)-positive cancers as well as other platform developments that support versatility for the potential treatment of several diverse cancers.ĭr. The presentation will highlight data from clinical trials evaluating CUE-101, the company’s lead clinical candidate from the CUE-100 series, in patients with human papilloma virus positive recurrent/metastatic head and neck squamous cell carcinoma (HPV+ R/M HNSCC) as a monotherapy and in combination with pembrolizumab. Levisetti will present an overview of Cue Biopharma’s Immuno-STAT™ (Selective Targeting and Alteration of T cells) platform including the interleukin 2 (IL-2)-based CUE-100 series of biologics designed to enable selective targeting of IL-2 to tumor-specific T cells. Session: Session IX – IL-2 in Cancer Therapyĭate and time: September 17, 2022, 9:00 am CETĭr. Presenter: Matteo Levisetti, M.D., senior vice president, Clinical Development, Cue Biopharma Presentation title: Leveraging the Immuno-STAT platform to enhance anti-tumor immunity by selectively delivering IL-2 to tumor-specific T cells Location: Centre international de Conférence Sorbonne Université, Paris, France (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate tumor-specific T cells directly within the patient’s body, announced today members of their management and scientific teams will participate in two scientific conferences this September, The Promise of Interleukin-2 Therapy taking place September 14-17 in Paris, France and the Next Generation Protein Therapeutics Summit, held in Boston, Massachusetts and virtually on September 28-30.
07, 2022 (GLOBE NEWSWIRE) - Cue Biopharma, Inc.
0 kommentar(er)
